Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658567 · ClinicalTrials.gov registry record · Phase 3
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT00658567 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 123 participants.
The verdict
NCT00658567, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
Interventions
- DRUG Pimavanserin tartrate (ACP-103)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658567
The ClinicalTrials.gov registry entry for NCT00658567 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin tartrate (ACP-103) is the first listed.
NCT00658567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658567 about?
NCT00658567 is a clinical study titled "A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis". This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
What is the current status of trial NCT00658567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2008-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00658567?
The interventions under investigation include: Pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT00658567?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.